Skip to main content
. 2024 May 15;10(10):e31192. doi: 10.1016/j.heliyon.2024.e31192

Table 2.

Investigating the relationship between ESPL1 mRNA expression and clinical characteristics in patients with ESPL1 from the TCGA_BLCA_mRNA dataset.

Clinical features ESPL1 mRNA Expression
t (t-test) or F(ANOVA test) p value
Number Mean SD
Age 2.411 0.0163
>60 315 3.182 0.9637
≤60 112 2.920 1.055
Sex 1.276 0.2027
Male 311 3.151 1.004
Female 116 3.013 0.9650
BMI 0.3409 0.7333
≥30 86 3.085 1.036
<30 279 3.127 0.9747
Race 1.730 0.1786
White 341 3.103 1.039
Asian 44 3.051 0.8993
Black or African American 24 3.292 0.7342
Clinical stage 1.335 0.2626
Stage I 2 1.783 1.493
Stage II 134 3.086 0.9847
Stage III 147 3.158 0.9873
Stage IV 142 3.100 1.002
Grade 0.3563 0.0004
High Grade 403 3.148 0.9761
Low Grade 21 2.367 1.050
Diagnosis_subtype 1.859 0.0638
Non-Papillary 285 3.168 0.9968
Papillary 137 2.977 0.9824
Lymphovascular_invasion_present 1.590 0.1128
No 133 3.239 0.9657
Yes 160 3.055 1.002
Smoker 0.03775 0.9699
No 194 3.115 0.9566
Yes 233 3.112 1.026
Primary_therapy_outcome_success 0.2213 0.8815
CR 154 3.188 0.9389
PR 16 3.229 0.9063
PD 43 3.085 0.9108
SD 22 3.272 1.285
Radiation_therapy 0.1486 0.8820
No 268 3.173 0.9829
Yes 10 3.220 0.3110
Pathologic_M 0.3545 0.7233
M0 206 3.118 1.014
M1 11 3.006 1.068
Pathologic_N 0.3695 0.7750
N0 248 3.136 0.9860
N1 49 3.111 1.010
N2 76 3.094 0.9716
N3 8 2.771 1.270
Pathologic_T 1.144 0.3196
T1&T2 127 3.052 0.9923
T3 205 3.152 0.9832
T4 61 2.944 1.066